Denied Eylea? You Still Have Options.
Eylea (aflibercept) is an anti-VEGF injection used to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal conditions — and insurance denials are a real obstacle, particularly when vision loss can progress quickly. Insurers often require prior authorization for Eylea, and many push step therapy — meaning they want you to try a lower-cost anti-VEGF agent like Avastin (bevacizumab, used off-label) or Lucentis first. Some formularies also limit the frequency of covered injections.
Option 1: Appeal Your Denial
Your ophthalmologist or retinal specialist can document why Eylea specifically — rather than a compounded or lower-cost alternative — is medically appropriate for your condition. For retinal conditions where vision is at stake, urgency can be argued compellingly. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Anti-VEGF research for retinal conditions is active, with trials studying aflibercept formulations (including the higher-dose Eylea HD), next-generation therapies, and combination approaches. Participating in a trial may give you access to these therapies at no cost. Search ClinicalTrials.gov for "aflibercept," "wet AMD," or "diabetic macular edema" to see what's enrolling near you.
Option 3: Patient Assistance Programs
Regeneron, Eylea's manufacturer, offers the Regeneron Assistance Program for eligible patients who need help with access or cost. The American Macular Degeneration Foundation (macular.org) and BrightFocus Foundation (brightfocus.org) also provide resources and connections to financial assistance for people managing retinal conditions.
For a complete guide to Eylea financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Eylea.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Eylea denied?
The most common reason is step therapy — your insurer wants you to try a less expensive anti-VEGF drug first, often Avastin (bevacizumab), which is cheaper and used off-label for retinal conditions. Eylea may also be denied for missing prior authorization, frequency limitations (the plan may cover fewer injections per year than your doctor recommends), or formulary restrictions. Your denial letter will specify the reason, which is your starting point for appeal.
Can I get Eylea through a clinical trial?
Clinical trials in retinal disease often study aflibercept formulations, biosimilars, or next-generation anti-VEGF therapies. If a trial is studying Eylea or a related drug for your condition, eligible participants typically receive the treatment at no cost. Your retinal specialist will know which trials are realistic for your situation. You can also search ClinicalTrials.gov for currently enrolling studies.
How long does an Eylea appeal take?
Standard appeals are typically decided within 30 days. If your vision situation is urgent, your doctor can request expedited review, which must be decided within 72 hours. An independent external review, if needed, usually resolves within 45 days. Given how quickly retinal conditions can change, it's worth discussing interim options with your specialist while your appeal is pending. Talk to your doctor before making any decisions about your treatment.